Mosapride: In gastrointestinal disorders

Drugs

Volumn 68, Issue 7, 2008, Pages 981-991

  Curran, Monique P ^a,b   Robinson, Dean M ^a,b  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

^b WOLTERS KLUWER HEALTH   (United States)

Author keywords

Adis Drug Profiles; Gastrointestinal disorders, treatment; Mosapride, general

Indexed keywords

CISAPRIDE; ERYTHROMYCIN; FAMOTIDINE; FLECAINIDE; ITOPRIDE; MOSAPRIDE CITRATE; MOTILIN; OMEPRAZOLE; PANTOPRAZOLE; POTASSIUM CHANNEL; PROKINETIC AGENT; TANDOSPIRONE; TEPRENONE;

ABDOMINAL PAIN; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHRONIC GASTRITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG INDICATION; DRUG TOLERABILITY; DYSPEPSIA; EOSINOPHILIA; GASTROINTESTINAL DISEASE; HEADACHE; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPOKALEMIA; LONG QT SYNDROME; MAJOR CLINICAL STUDY; MALAISE; OPEN STUDY; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; STOMACH MOTILITY; STOMACH PAIN; SYMPTOMATOLOGY; TORSADE DES POINTES; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; XEROSTOMIA;

BENZAMIDES; DYSPEPSIA; GASTRITIS; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL AGENTS; GASTROINTESTINAL DISEASES; HUMANS; MORPHOLINES;

EID: 43249127643     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200868070-00007     Document Type: Review

References (61)

1. Mizuta Y, Shikuwa S, Isomoto H, et al. Recent insights into digestive motility in functional dyspepsia. J Gastroenterol 2006 Nov; 41 (11): 1025-40
2. Thompson WG, Longstreth GF, Drossman DA, et al. Functional bowel disorders and functional abdominal pain. Gut 1999 Sep; 45 Suppl. 2: II43-7
3. Grundy D, AL-Chaer ED, Aziz Q, et al. Fundamentals of neurogastroenterology: basic science. Gastroenterology 2006; 130 (5): 1391-411
4. Makimoto N, Sukurai-Yamashita Y, Furuichi A, et al. In vivo assessment of acceleration of motor activity associated with acetylcholine release via 5-hydroxytriptamine. Jpn J Pharmacol 2002; 90: 28-35
5. Carlsson L, Amos GJ, Andersson B, et al. Electrophysiological characterization of the prokinetic agents cisapride and mosapride in vivo and in vitro: implications for proarrhythmic potential? J Pharmacol Exp Ther 1997 Jul; 282 (1): 220-7
6. 4 agonists cisapride, mosapride, and CJ-033466, a novel potent compound, exhibit different human ether-a-go-go-related gene (hERG)-blocking activities. J Pharmacol Sci 2007 Oct; 105 (2): 207-10
7. Potet F, Bouyssou T, Escande D. Gastrointestinal prokinetic drugs have a different affinity for the human cardiac human ether-à-gogo K+ channel. J Pharmacol Exp Ther 2001; 289 (3): 1007-12
8. Yoshida N, Kato S, Ito T. Mosapride citrate: gastroprokinetic. Drugs Future 1993; 18 (6): 513-5
9. Karasawa T, Yoshida N, Furukawa K, et al. Comparison of gastrokinetic effects of AS-4370, cisapride and BRL24924. Eur J Pharmacol 1990 Jul 6; 183: 2181
10. Yoshida N, Omoya H, Furukawa K, et al. Pharmacological studies on mosapride citrate (AS-4370), a gastroprokinetic agent (1): comparison with cisapride and metoclopramide [in Japanese]. Jpn Pharmacol Ther 1993; 21 (9): 249-64
11. 2 receptor antagonist properties. Arch Int Pharmacodyn Ther 1989; 300: 51-67
12. Yoshida N, Omoya H, Kato S, et al. Pharmaocological effects of the new gastroprokinetic agent mosapride citrate and its metabolite in experimental animals. Arzneimittelforschung 1993; 43 (10): 1078-83
13. Hamelin B, Bredberg E, Röhss K, et al. Effects of mosapride on oesophageal motility in humans [abstract no. A51]. Dig Dis Sci 1996 Sep; 41 (9): 1892
14. Mitsufuji S, Nakao H, Taniguchi J, et al. Effect of mosapride citrate on esophageal motility in healthy subjects and patients with gastroesophageal reflux disease [in Japanese]. Prog Med 2002; 22 (3): 801-5
15. Ruth M, Finizia C, Cange L, et al. The effect of mosapride on oesophageal motor function and acid reflux in patients with gastro-oesophageal reflux disease. Eur J Gastroenterol Hepatol 2003 Oct; 15 (10): 1115-21
16. Cho YK, Choi M-G, Han HW, et al. The effect of mosapride on esophageal motility and bolus transit in asymptomatic volunteers. J Clin Gastroenterol 2006 Apr; 40 (4): 286-92
17. Kanaizumi T, Nakano H, Matsui Y, et al. Prokinetic effect of AS-4370 on gastric emptying in healthy adults. Eur J Clin Pharmacol 1991; 41 (4): 335-7
18. Suyama T, Tokubayashi F, Omatsu Y, et al. Accelerating effect of AS-4370 (mosapride) on gastric emptying time (double sampling test method) and its clinical efficacy on chronic gastritis accompanied by epigastric symptoms [in Japanese]. Jpn Arch Intern Med 1993; 40 (7): 175-83
19. Wei W, Ge Z-Z, Lu H, et al. Effect of mosapride on gastrointestinal transit time and diagnostic yield of capsule endoscopy. J Gastroenterol Hepatol 2007 Oct; 22 (10): 1605-8
20. 4 agonist therapy reduces response fluctuations in Parkinson's disease. Parkinsonism Relat Disord 2005; 11 (8): 499-502
21. Asakawa H, Hayashi I, Fukui T, et al. Effect of mosapride on glycemic control and gastric emptying in type 2 diabetes mellitus patients with gastropathy. Diabetes Res Clin Pract 2003; 61 (3): 175-82
22. Yamada M, Hongo M. Effects of prokinetic agents: comparison between AS4370 and EM523L. Gastroenterol Jpn 1993 Dec; 28 (6): 836
23. Inui A, Yoshikawa T, Nagai R, et al. Effects of mosapride citrate, a 5-HT4 receptor agonist, on colonic motilit in conscious guinea pigs. Jpn J Pharmacol 2002; 90: 313-20
24. Liu Z, Sakakibara R, Odaka T, et al. Mosapride citrate, a novel 5-HT4 agonist and partial 5-HT3 anatgonist, ameliorates constipation in parkinsonian patients. Mov Disord 2005; 20 (6): 680-6
25. 4 agonist, in chronically lumbosacral denervated guinea pigs. J Smooth Muscle Res 2006; 42 (5): 139-47
26. 4 agonist, mosapride, enhances intrinsic rectorectal and rectonal reflexes after removal of extrinsic nerves in guinea pigs. Am J Physiol Gastrointest Liver Physiol 2005; 289: G351-60
27. Ruth M, Hamelin B, Röhss K, et al. The effect of mosapride, a novel prokinetic, on acid reflux variables in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1998 Jan; 12 (1): 35-40
28. Itoh H, Nagano T, Takeyama M. Effects of mosapride citrate on human plasma levels of motilin, gastrin, somatostatin, and secretin. Biol Pharm Bull 2001 Sep; 24 (9): 1072-5
29. Hayakawa A, Kawahara K, Ueda Y, et al. Clinical study of AS-4370 in non-ulcer dyspepsia: effects of AS-4370 on upper abdominal symptoms and on hormones [in Japanese]. Rinsho Iyaku 1992; 8 (3): 639-45
30. Kii Y, Ito T. Effects of 5-HT4-receptor agonists, cisapride, mosapride citrate, and zacopride, on cardiac action potentials in guinea pig isolated papillary muscles. J Cardiovasc Pharmacol 1997 May; 29 (5): 670-5
31. Katoh T, Saitoh H, Ohno N, et al. Drug interaction between mosapride and erythromycin without electrocardiographic changes. Jpn Heart J 2003 Mar; 44 (2): 225-34
32. Horii S, Takeda T, Fujimoto Y, et al. Clinical study on safety of mosapride in combination therapy with psychiatric drugs [in Japanese]. Rinsho Iyaku 2000; 16 (2): 153-62
33. Takeuchi Y, Watanabe H, Imawari M. Mosapride citrate, a serotonin HT4 selective agonist, beneficially affects pharmacokinetics of proton pump inhibitor [abstract no. T1693]. Gastroenterology 2005 Apr; 128 (4 Suppl. 2): A-531
34. Sakashita M, Yamaguchi T, Miyazaki H, et al. Pharmacokinetics of the gastrokinetic agent mosapride citrate after single and multiple oral administrations in healthy subjects. Arzneimittelforschung 1993; 43 (8): 867-72
35. Ogihara T, Higaki J, Azuma J, et al. Pharmacokinetic study of AS-4370 in the elderly: comparison with the young [in Japanese]. Rinsho Iyaku 1994; 10 (11): 2489-97
36. Dainippon Pharmaceutical Co., Ltd. Gasmotin®: mosapride citrate preparation. Prescribing information. Osaka, 2004
37. Miyoshi A, Yoshida Y, Masamune O, et al. Phase II study of two dosage regimens of AS-4370 tablet: randomised comparison of doses taken before and after meals [in Japanese]. Rinsho Iyaku 1998; 14 (6): 1025-36
38. Misawa T, Okabe H, Chijiiwa Y, et al. Clinical study of AS-4370 on upper abdominal symptoms in chronic gastritis [in Japanese]. Rinsho Iyaku 1993; 9 (9): 2167-76
39. Toyota T, Hongo M, Sato M, et al. Clinical evaluation of mosapride citrate (AS-4370) on dyspepsia symptoms in chronic gastritis [in Japanese]. Rinsho Iyaku 1993; 9 (8): 1887-95
40. Miyoshi A, Miwa T, Harasawa S, et al. Dose-finding study of AS-4370 (mosapride citrate) in patients with chronic gastritis [in Japanese]. Rinsho Iyaku 1998; 14 (6): 1069-90
41. Miyoshi A, Miwa T, Harasawa S, et al. Clinical evaluation of AS-4370 on epigastric symptoms associated with chronic gastritis [in Japanese]. Rinsho Iyaku 1998; 14 ( 6): 1037-53
42. Miyoshi A, Miwa T, Harasawa S, et al. Dose finding study of AS-4370 in patients with non-ulcer dyspepsia [in Japanese]. Rinsho Iyaku 1990 Nov; 6: 2295-310
43. Miyoshi A, Sekiguchi T, Miwa T, et al. Clinical assessment of AS-4370 in the treatment of reflux oesophagitis: dose-comparison study by randomization [in Japanese]. Rinsho Iyaku 1993; 9 ( 6): 1327-41
44. Hongo M. Initial approach and pharmacotherapy for functional dyspepsia: a large clinical trial in Japan [abstract no. T1247, plus poster]. Gastroenterology 2006 Apr; 130 (4 Suppl. 2): 506
45. Hallerbäck BI, Bommelaer G, Bredberg E, et al. Dose finding study of mosapride in functional dyspepsia: a placebo-controlled, randomized study. Aliment Pharmacol Ther 2002 May; 16 (5): 959-67
46. Kinoshita Y, Hashimoto T, Kawamura A, et al. Effects of famotidine, mosapride and tandospirone for treatment of functional dyspepsia. Aliment Pharmacol Ther 2005 Jun; 21 Suppl. 2: 37-41
47. Otaka M, Jin M, Odashima M, et al. New strategy of therapy for functional dyspepsia using famotidine, mosapride and amitriptyline. Aliment Pharmacol Ther 2005 Jun; 21 Suppl. 2: 42-6
48. Seno H, Nakase H, Chiba T. Usefulness of famotidine in functional dyspepsia patient treatment: comparison among prokinetic, acid suppression and antianxiety therapies. Aliment Pharmacol Ther 2005 Jan 1; 21 Suppl. 2: 32-6
49. Amarapurkar DN, Rane P. Randomised, double-blind, comparative study to evaluate the efficacy and safety of ganaton (itopride hydrochloride) and mosapride citrate in the management of functional dyspepsia. J Indian Med Assoc 2004 Dec; 102 (12): 735-7, 760
50. Miyoshi A, Sekiguchi T, Harasawa S, et al. Clinical evaluation of mosapride (AS-4370) on gastroesophageal reflux disease: multi-centered double-blind comparative study with cisapride [in Japanese]. Rinsho Iyaku 1998; 14 (6): 1055-68
51. Madan K, Ahuja V, Kashyap PC, et al. Comparison of efficacy of pantoprazole alone versus pantoprazole plus mosapride in therapy of gastroesophageal reflux disease: a randomized trial. Dis Esophagus 2004; 17 (4): 274-8
52. Kanaizumi T, Nakano H, Kuriya N. Clinical evaluation of AS-4370 in ambulatory patients with epigastric digestive tract disorder after gastric surgery by double-blind study [in Japanese]. Rinsho Iyaku 1992; 8 (7): 1559-68
53. Kanaizumi T, Nakano H. Clinical evaluation of long-term administration of mosapride citrate (AS-4370) in postoperative ambulatory patients with epigastric digestive tract disorders [in Japanese]. Rinsho Iyaku 1993; 9 (8): 1879-86
54. Kanaizumi T, Nakano H, Kuriya N. Clinical evaluation of AS-4370 in hospitalized patients with epigastric symptoms after gastric surgery in a double-blind comparative study [in Japanese]. Rinsho Iyaku 1992; 8 (12): 2831-40
55. 4 receptor agonist (mosapride citrate) [in Japanese]. Nippon Rinsho 2006; 64 (8): 1491-4
56. Hiyama T, Yoshihara M, Matsuo K, et al. Treatment of functional dyspepsia with serotonin agonists: a meta-analysis of randomized controlled trials. J Gastroenterol Hepatol 2007 Oct; 22 (10): 1566-70
57. Oikawa T, Takemoto Y, Haramu K. Postmarketing surveillance of mosapride citrate (Gasmotin®) in patients with non-ulcer dyspepsia on long-term administration [in Japanese]. Rinsho Iyaku 2005; 21 (8): 831-7
58. Ohki R, Takahashi M, Mizuno O, et al. Torsades de pointes ventricular tachycardia induced by mosapride and flecainide in the presence of hypokalemia. Pacing Clin Electrophysiol 2001 Jan; 24 (1): 119-21
59. Dainippon Pharmaceutical Co. Ltd. Launch of Gasmotin® in South Korea [media release]. Available from URL: http://www.dainippon-pharm.co.jp [Accessed 2008 Mar 14]
60. Eisai TMCL. Eisai submits application for gastroprokinetic agent Gasmotin® in Thailand [media release]. Available from URL: http://www.eisai.co.jp [Accessed 2008 Jan 17]
61. Dainippon Sumitomo Pharma Co. Ltd., Eisai Co.. Dainippon Sumitomo Pharma and Eisai signed licensing agreement for Gasmotin®, a gastroprokinetic agent, for countries in Asia including ASEAN members [online]. Available from URL: http://www.ds-pharma.co.jp [Accessed 2008 Jan 17]